retatrutide clinical trials weight loss Eli Lilly infiltrates anti-obesity market as Phase III trial for begins New Phase 3 retatrutide data

" ?"

Depth arrives through branching paths, optional modifiers, and pacing toggles that shift the challenge without obscuring clarity

However, while the benefits of achieving a healthier weight cannot be overstated, there are some important nuances to consider when using these medications

The SUMMIT trial, involving 731 individuals with HFpEF and obesity followed for a median of 104 weeks, revealed a 38% decrease in the composite endpoint of cardiovascular mortality or heart-failure deterioration events (HR: 0.62, 95%CI: 0.41-0.95, P = 0.026), driven primarily by fewer worsening heart-failure events (8.0% vs